Mouse Anti-EGFR Recombinant Antibody (clone 14E1) (CAT#: HPAB-S0023-YC)

Figure 1 In vitro expression of full-length 14E1 and 14E1A monoclonal antibody.

(a) Western blot analysis of supernatants from transiently transfected 293F cells expressing 14E1 and 14E1A antibody. Supernatant from 293F cells transfected with an empty pZAC2.1 vector (EV) plasmid served as a negative control. The samples were separated by SDS-polyacrylamide gel electrophoresis (PAGE) under (a) nonreducing and (b) reducing conditions and subsequently probed with a goat anti-mouse immunoglobulin G (IgG;H+L) polyclonal antibody. Under reducing conditions, HC refers to the heavy chain and LC refers to the light chain.

Ho, D. T., Wykoff-Clary, S., Gross, C. S., Schneider, D., Jin, F., Kretschmer, P. J., & Hermiston, T. W. (2009). Growth inhibition of an established A431 xenograft tumor by a full-length anti-EGFR antibody following gene delivery by AAV. Cancer gene therapy, 16(2), 184-194.

Figure 2 14E1 monoclonal antibody inhibits the in vitro cell proliferation of A431 cells.

The 14E1 antibody significantly inhibited the proliferation of the A431 cells in a dose-dependent manner with a maximum inhibition of ~40% at a concentration of 0.75 μg/ml.

Ho, D. T., Wykoff-Clary, S., Gross, C. S., Schneider, D., Jin, F., Kretschmer, P. J., & Hermiston, T. W. (2009). Growth inhibition of an established A431 xenograft tumor by a full-length anti-EGFR antibody following gene delivery by AAV. Cancer gene therapy, 16(2), 184-194.

Figure 3 Expression of 14E1 and 14E1A antibody in mouse serum and hind limb muscle following delivery by adeno-associated virus (AAV) 2/1.

(a) Athymic nude mice were given a single, bilateral intramuscular (i.m.) injection of AAV2/1-14E1 or AAV2/1-14E1A into the tibialis and gastrocnemius muscle. Tibialis muscle sections were prepared 84 days after injection and examined by immunohistochemical staining for Etag.Magnification,×200. (b) Western blot analysis of whole-cell lysates prepared from the tibialis muscle of nude mice injected with AAV2/1-14E1 or AAV2/1-14E1A. (c) AAV2/1 14E1Etag-pZAC was injected i.m. into mice, into both the tibialis and gastrocnemius of each hind limb of each animal, with a total dosage of 1×10¹¹ genome content (GC) per mouse. (d) Either AAV2/1-14E1 or AAV2/1-14E1A was injected i,m. into mice, into both the tibialis and gastrocnemius of each hind limb of each animal, with a total dosage of 1×10¹¹ GC per mouse.

Ho, D. T., Wykoff-Clary, S., Gross, C. S., Schneider, D., Jin, F., Kretschmer, P. J., & Hermiston, T. W. (2009). Growth inhibition of an established A431 xenograft tumor by a full-length anti-EGFR antibody following gene delivery by AAV. Cancer gene therapy, 16(2), 184-194.

Figure 4 Adeno-associated virus (AAV) 2/1-mediated delivery of 14E1 inhibits the growth of early-stage tumors and prolongs survival.

A, No Etag staining could be detected in the tumor only sample. B, AAV2/1-14E1 was injected intramuscularly into athymic nude mice at different time points relative to A431 tumor challengeC, As shown by the day -28 group, high serum levels of the 14E1 antibody at the time of tumor injection significantly prevented the enlargement of tumors. D, The significant inhibition of tumor growth resulted in dramatically improved survival time for all three 14E1 treatment groups.

Ho, D. T., Wykoff-Clary, S., Gross, C. S., Schneider, D., Jin, F., Kretschmer, P. J., & Hermiston, T. W. (2009). Growth inhibition of an established A431 xenograft tumor by a full-length anti-EGFR antibody following gene delivery by AAV. Cancer gene therapy, 16(2), 184-194.

Figure 5 Adeno-associated virus (AAV) 2/1-mediated delivery of 14E1 inhibits the growth of well-established tumors and prolongs survival.

The positive control day -7 group significantly prevented tumor growth. In both the days +13 and +20 groups, tumor growth was significantly inhibited by treatment with the AAV2/1-14E1 by day 43 and resulted in significantly enhanced survival versus the tumor alone group (P<0.03) or the ablated control group (P<0.05) by day 56.

Ho, D. T., Wykoff-Clary, S., Gross, C. S., Schneider, D., Jin, F., Kretschmer, P. J., & Hermiston, T. W. (2009). Growth inhibition of an established A431 xenograft tumor by a full-length anti-EGFR antibody following gene delivery by AAV. Cancer gene therapy, 16(2), 184-194.